AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 72 min read$PCVX

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte (PCVX) priced offerings: 7.8M shares at $64 each, $500M in convertible notes due 2032. Proceeds (~$1B total) to fund clinical trials, manufacturing, and general corporate purposes. Offerings expected to close Oct 9, 2026. Notes carry 1.5% interest, convertible at $89.60/share.

Original reporting
globenewswire.com
Published Oct 7, 2026, 2:48 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 2:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PCVX
Bearish
high confidence
Mentioned
$PCVX
Relevance
9/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$PCVXBearishHigh
01

Why it matters

The $1 billion capital raise is the first major financing round for Vaxcyte, signaling confidence in its pipeline and setting a valuation baseline for future milestones.

02

Market read

The offering size and terms are material for investors; the news will likely drive immediate price action and set the stage for upcoming trial data releases.

03

What to watch

Potential conversion features of the notes and warrant over‑allotment options could further affect share count and price dynamics.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Vaxcyte is a clinical‑stage vaccine company advancing its PCV programs, including VAX‑31 adult and pediatric trials.

Company-level read

Ticker impact

$PCVXBearishHigh confidence
Context

Announced pricing of $1 billion concurrent public offerings of common stock, pre‑funded warrants and convertible senior notes.

Expected impact

potential short‑term pressure as the market prices in dilution, followed by upside if trial data materializes.

Evidence & confidence

Large primary capital raise is material news; dilution is immediate, but the funded pipeline offers upside catalysts.

Market effects

Sector

Provides a benchmark for biotech financing, may encourage similar raise activity in the vaccine sector.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Adds to overall biotech fundraising trends but unlikely to move broader indices.

Counterpoint

What could challenge this read

The dilution could outweigh near‑term pipeline upside, making the stock a short candidate until data de‑risking.

Key entities

  • company
    Vaxcyte, Inc.

    Clinical‑stage vaccine innovator issuing equity, warrants and convertible notes.

  • financial_institution
    Jefferies, Leerink Partners, BofA Securities, etc.

    Joint book‑running managers for the offerings.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 7
$PCVXMedAI 8/10

Vaxcyte, Inc. (PCVX) Prices ~$1.0B Equity And 1.50% Converts

Vaxcyte, Inc. (PCVX) raised ~$1.0B through a share offering, warrant sales, and convertible notes. The company issued 7.41M shares at $64, 400K pre-funded warrants, and $500M of 1.50% convertible notes due 2032. Proceeds will fund Phase 3 trials, scale-up, and U.S. adult launch prep, according to the company.

tradingview.com1 min
OCT 6
$PCVXHighAI 9/10

As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

Vaxcyte (PCVX) shares fell 10% after announcing a $1 billion raise, split between $500 million in stock and $500 million in convertible notes, following a Phase 3 trial success. The funds will support VAX-31 trials and manufacturing. Operating cash burn rose from $121M in 2021 to $656M in 2025. The company expects to file for approval in 2028.

finance.yahoo.com2 min
OCT 6
MedAI 8/10

Vaxcyte Stock Jumps 31% as VAX-31 Clears Phase 3 OPUS-1

Vaxcyte's stock rose 30.7% after its pneumococcal vaccine, VAX-31, met all primary endpoints in a Phase 3 trial, potentially competing with Pfizer's and Merck's vaccines. The company raised $1 billion via equity-linked financing. VAX-31 covers 31 serotypes, more than its competitors, but missed some thresholds against Merck's vaccine. Full data and regulatory feedback are pending.

financefeeds.com3 min
OCT 6
HighAI 9/10

Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results

Vaxcyte's VAX-31 pneumococcal vaccine met all primary endpoints in a phase 3 trial, showing noninferiority to Pfizer's and Merck's vaccines. The stock surged 57% pre-market. VAX-31 demonstrated superior immune responses on unique strains and met safety criteria. The company plans FDA submission in 2028.

finance.yahoo.com2 min
OCT 6
$PCVXHighAI 8/10

BofA raises Vaxcyte stock price target to $146 on OPUS-1 data

BofA Securities raised its price target on Vaxcyte (PCVX) to $146 from $130, maintaining a Buy rating. The stock is currently trading at $73.82. The move follows positive OPUS-1 trial results, which met primary endpoints and showed strong performance against competitors. Analysts have revised earnings upwards, but some suggest the stock may be overvalued. Vaxcyte also announced new executive appointments and adjusted its VAX-31 launch timeline to 2029.

investing.com1 min